Gal-3 Inhibitors via Modular Molecular Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current synthetic inhibitors for Galectin-3 (Gal-3) are being explored for antifibrotic effects, but there is a need for more effective compounds that can specifically target Gal-3 to treat various fibrotic and inflammatory diseases.
Innovation Solution
The development of novel compounds of Formula (I) and their pharmaceutically acceptable salts, which inhibit Gal-3, offering a potential therapeutic approach for fibrotic and inflammatory conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current synthetic inhibitors for Galectin-3 are used, then some antifibrotic effects are achieved, but the inhibition effectiveness is insufficient and specificity is inadequate
Solution Approach 1:
The patent modifies the chemical parameters of Gal-3 inhibitors by changing the core structure from natural lactose to synthetic analogs with modified glycosidic bonds (α-glycosidic, C-glycoside, O-glycoside variations). This structural parameter change enhances binding affinity and inhibition effectiveness while maintaining manageable structural complexity through systematic molecular design
Solution Approach 2:
The invention creates composite inhibitor molecules combining galactose-like moieties with various aromatic rings (phenyl, naphthyl, heteroaryl), alkyl chains, and functional groups in specific configurations. These composite structures achieve superior inhibition effectiveness by optimizing multiple interaction points with Gal-3 while the modular design approach keeps synthesis complexity manageable
2Measurement precision
If more complex Gal-3 inhibitor compounds are developed to improve specificity, then binding affinity increases, but synthesis difficulty and manufacturing complexity increase
Solution Approach 1:
The Gal-3 inhibitor compounds are segmented into distinct functional modules: a galactose-like core structure, aromatic ring systems (Ar1, Ar2), alkyl chains (R1, R2, R3), and optional functional groups. This segmentation allows independent optimization of each module for binding specificity while enabling modular synthesis approaches that simplify manufacturing by allowing separate preparation and assembly of components
Solution Approach 2:
The patent applies local quality modifications by introducing specific functional groups at particular positions on the molecular structure (e.g., hydroxyl groups at C3/C4 positions, methoxy groups, halogen substituents). These localized modifications enhance binding specificity to Gal-3's carbohydrate recognition domain without requiring complete restructuring of the entire molecule, thus maintaining synthesis feasibility
Data Source
AI summary
The present disclosure relates to compounds of Formula (I), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions. (Formula (I))